Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

It comes as new analysis by Asthma and Lung UK found lung diseases were responsible for one in eight emergency hospital ...

ANGLE plc (GB:AGL) has released an update. ANGLE plc’s recent study highlights the potential of dual CTC-DNA and ctDNA analysis in enhancing ...

Treatment options for prostate cancer vary depending on the ... often dismissing their symptoms or feeling embarrassed to ...

Medically reviewed by Marla Anderson, MD Lung cancer causes cancer cells to develop a tumor in the lungs' tissues. Lung ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Even current smokers who quit after being diagnosed with cancer are better able to heal and respond to treatment, reducing the chance of death from some cancers by up to 40 percent. Think you need a ...

NEW YORK (WABC) -- A mother from Queens is opening up about motherhood amid her battle against an aggressive form of cancer.

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...